One hundred twenty-five patients were enrolled in a study of growth retarded pre-pubertal (at baseline) children with CRI and were randomized to recieve either rhGH 0.5 mg/kg/day SC or an equal volume of placebo for two years. After two years all patients received rhGH. Treatment was paused in 24 children after reaching mid-parental target height percentile, of whom 17(71%) required re-initiation of rhGH because of a substantial decrease in standardized height. Long-term (5 year) treatment of 35 children led to a significant (p<0.0001) improvement in standardized height from -2.8 at baseline to -0.9 at 5 years. Adult height potential was not adversely impacted with a Δ height age minus Δ bone age at 5 years of +0.3 (N=21). The mean calculated creatinine clearance decreased from 36.2 ± 19.0 mL/min/1.73m2 at baseline to 27.2 ± 18.8 mL/min/1.73m2 at 5 years (p=.0007) which would be consistent with the natural history of CRI children. There was a small increase in the median fasting and 2 hour post-prandial plasma insulin levels during treatment. Development of avascular necrosis of the femoral head, a known compliction of renal osteodystropy was observed in several patients. Presence of AVN was noted on hip x-rays prior to initiation of rhGH in three patients. Because baseline x-rays were not available for most patients this finding requires further investigation. Forty-eight patients had renal transplants and 42 were treated with growth hormone prior to transplant. Thirty patients (23M, 7F) received at least 2 years of rhGH therapy before transplant. Their mean±SD Ht SDS was -2.8± 0.9 at baseline and -1.2 ± 1.2 at transplant. This is a significant (p<0.0001) mean improvement of 1.6 ± 1.0 in Ht SDS after a mean of 4.3 ± 1.7 yr. of rhGH therapy. Long-term rhGH treatment in children with CRI improves the potential of children with CRI achieving target adult height.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fine, R., Kohaut, E., Kuntze, J. et al. Long-Term Growth Hormone Treatment of Growth Retarded Children With Chronic Renal Insufficiency (CRI) † 1798. Pediatr Res 43 (Suppl 4), 307 (1998). https://doi.org/10.1203/00006450-199804001-01821
Issue Date:
DOI: https://doi.org/10.1203/00006450-199804001-01821